Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-05-14
Butterfly Network, Inc.
Butterfly sells handheld ultrasound devices, cloud workflow software, and chip-based imaging development offerings for healthcare providers and partners.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Real product, real optionality, still proof required
The setup is a real product plus a plausible mix shift, not a pure concept stock. Upside comes from turning handheld ultrasound into workflow and licensing revenue before larger imaging vendors blunt differentiation.

Analysis

Thesis
Butterfly has a credible path from niche handheld-ultrasound vendor to higher-quality imaging platform if iQ3 adoption, enterprise workflow, and Embedded licensing become repeatable enough to turn a device story into a recurring mix-shift story.
Last Economy Alignment
AI makes ultrasound easier for more clinicians to use, and Butterfly controls the probe, workflow, and regulatory surface. That is meaningfully positive, though not unconstrained because incumbents can bundle and regulators still gate each new use case.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.7x (from 5 most recent analyses)
Reasoning
This is a 2-5x setup, not a 10x one. The upside comes from three layers compounding together: more core probe adoption, better software attach into enterprise workflow, and a repeatable Embedded channel that monetizes the chip beyond direct device sales. If those layers prove durable, investors should pay more for recurring mix and lower financing risk, but regulation and incumbent imaging bundles keep this below a full software-platform outcome.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly has a real product; it does. The real question is whether software, Embedded, and decentralized-care channels become repeatable before larger imaging vendors blunt differentiation or regulators slow the roadmap. Supply concentration in its chip-and-probe chain and the still-lumpy nature of Embedded revenue are the most important practical constraints on the upside case.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They own the handheld probe, the workflow software, and the approvals that make bedside ultrasound easier to use as AI improves. The risk is that bigger imaging vendors can bundle similar tools and each new clinical use still has to clear regulators.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case